Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Oric Pharmaceuticals Inc (NQ: ORIC )

8.230 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Apr 29, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 0
Open 8.230
Bid (Size) 6.900 (1)
Ask (Size) 10.68 (3)
Prev. Close 8.230
Today's Range 8.230 - 8.230
52wk Range 4.940 - 16.65
Shares Outstanding 54,532,614
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Benzinga's 'Stock Whisper' Index: 5 Stocks Investors Secretly Monitor But Don't Talk About Yet
Each week, Benzinga's Stock Whisper Index uses a combination of proprietary data and pattern recognition to showcase five stocks just under the surface and warrant attention. 
Via Benzinga
ORIC Pharmaceuticals Announces First Patients Dosed Across Three Expansion Cohorts in Phase 1b Trial of ORIC-114 in Patients with Mutated NSCLC
From ORIC Pharmaceuticals
Via GlobeNewswire

Performance

YTD
-9.96%
-9.96%
1 Month
-36.35%
-36.35%
3 Month
-29.72%
-29.72%
6 Month
+29.20%
+29.20%
1 Year
+57.06%
+57.06%

More News

Read More
ORIC Pharmaceuticals Presents Preclinical Data on Two Programs at the 2024 American Association for Cancer Research (AACR) Annual Meeting
From ORIC Pharmaceuticals
Via GlobeNewswire
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
From ORIC Pharmaceuticals
Via GlobeNewswire
ORIC Pharmaceuticals Inc. (NASDAQ: ORIC) is a Stock Spotlight on 3/1
Via Investor Brand Network
Where ORIC Pharmaceuticals Stands With Analysts
Via Benzinga
ORIC Pharmaceuticals to Participate in Upcoming Investor Conferences
From ORIC Pharmaceuticals
Via GlobeNewswire
Micron To Rally Around 134%? Here Are 10 Top Analyst Forecasts For Thursday
Via Benzinga
These Analysts Revise Their Forecasts On ORIC Pharmaceuticals After Q4 Results
Via Benzinga
ORIC Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Operational Updates
From ORIC Pharmaceuticals
Via GlobeNewswire
ORIC Pharmaceuticals to Present at the Leerink Partners Global Biopharma Conference
From ORIC Pharmaceuticals
Via GlobeNewswire
ORIC Pharmaceuticals Announces Multiple Presentations at the 2024 American Association for Cancer Research (AACR) Annual Meeting
From ORIC Pharmaceuticals
Via GlobeNewswire
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
From ORIC Pharmaceuticals
Via GlobeNewswire
Why Butterfly Network Shares Are Trading Lower By 22%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Via Benzinga
Hormel Foods Reports Upbeat Earnings, Joins Pure Storage, Okta, Papa John's International And Other Big Stocks Moving Higher On Thursday
Via Benzinga
Topics Stocks
Exposures US Equities
ORIC Pharmaceuticals to Participate in the Citi 2024 Virtual Oncology Leadership Summit
From ORIC Pharmaceuticals
Via GlobeNewswire
MicroMarvel - ORIC Pharmaceutical - Fights Cancer
Via Talk Markets
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
From ORIC Pharmaceuticals
Via GlobeNewswire
ORIC Pharmaceuticals to Participate in Upcoming Investor Conferences
From ORIC Pharmaceuticals
Via GlobeNewswire
ORIC Pharmaceuticals Announces $125 Million Private Placement Financing
From ORIC Pharmaceuticals
Via GlobeNewswire
Final Boarding Call: 3 Stocks Set for a Sky-High Surge
Via InvestorPlace
ORIC Pharmaceuticals Provides Initial Phase 1b Data for ORIC-944, Operational Highlights for 2023, and Anticipated Upcoming Milestones
From ORIC Pharmaceuticals
Via GlobeNewswire
ORIC Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference
From ORIC Pharmaceuticals
Via GlobeNewswire
Initial Phase 1 Dose Escalation Data for ORIC-533 in Relapsed/Refractory Multiple Myeloma Demonstrates Clinical Activity and Strong Safety Profile Supporting Potential for Combination Development
From ORIC Pharmaceuticals
Via GlobeNewswire
3 Stocks at the Forefront of Personalized Medicine Trend
Via InvestorPlace
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.